Singer India Ltd
SINGERINDSinger India Ltd is coiled. The quarters are improving, yet the P/E sits at the 22nd percentile of its own 10-year range — the business is moving before the market.
The sharpest disagreement: profits are rising, but only 54% of the last 3 years' profit arrived as operating cash — the gap between the P&L and the bank account is the thing to watch.
The price is in a confirmed uptrend (4 weeks in) while the P/E sits at the 22nd percentile of its own 10-year range. Underneath, the last four quarters read improving, and 54% of the last 3 years' profit arrived as cash. What settles it: whether the cash starts following the profit.
Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.
Singer India Ltd trades at ₹77.7, in a confirmed uptrend and 4 weeks into that stage. That is +6.8% against its own 200-day average. It sits at 69% of a 52-week range of ₹65 to ₹83. On relative strength it has no relative-strength read yet.
Today the stock is in a confirmed uptrend — week 4 of stage 2, confirmed. At ₹77.7 it trades +6.8% versus its 200-day average and sits at 69% of its 52-week range (₹65–₹83).
Against the market, two honest reads. Cumulative: over the last 2 months the stock moved +11% while the NIFTY 500 moved −3% — ahead of the index over the full window. Recent form: no trailing-13-week read yet — the ribbon below is that same metric, week by week.
What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.
Valuation P/E is the price of ₹1 of annual profit: how many rupees the market pays for each rupee the company earns in a year.
Singer India Ltd trades at 25.9× P/E, near the bottom of its own range — cheaper only 22% of the time. Its long-run median P/E is 33.8×, measured across 10.1 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.
Today's P/E of 25.9× is near the bottom of its own range — cheaper only 22% of the time, against a long-run median of 33.8× measured over 10.1 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.
Put together: the multiple is low against its own past, so the story rests on the earnings line underneath it, not the multiple.
Stage: Mixed Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).
Singer India Ltd reads as mixed on its fundamental arc. Mixed — revenue growth is rising at +56.9% (single-quarter readings) while profit growth is decelerating from its peak at +45.7% (single-quarter readings) — the curves disagree, so the per-curve reads carry the story. The read is built from 9 quarters across 3 curves, on partial evidence.
Why it matters: when the curves disagree, the per-curve reads above matter more than any single verdict.
One or more growth curves carry a base-effect spike — a large year-on-year move off a near-zero or loss-making comparable quarter. Those spikes are capped before the classifier reads the trajectory, and shown pinned on the chart, so a single distorted quarter does not drive the stage call.
Return readings here are annual, not quarterly — read as level and direction only; they can confirm the growth curves but never drive the stage on their own.
A partial read: at least one curve is short, or the returns curve is not the computed quarterly series — hold the stage word a little more loosely.
| 1yr | 3yr | 5yr | 10yr | |
|---|---|---|---|---|
| Revenue | +28.9% | +6.6% | +6.1% | — |
| Profit | +85.7% | +17.6% | +3.4% | — |
| EPS | +70.8% | +14.7% | +0.7% | — |
4-Factor Sector Score
57.3/100 — rank 12 of 58 in Trading · 52% evidence confidence
Singer India Ltd scores 57.3 out of 100 against the 58 companies it is compared with in Trading, ranking 12. Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
The four contributions add to the total exactly: 26.1 + 10.2 + 10.1 + 10.9 = 57.3. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.
What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.
Revenue Revenue is the top line: everything the company billed its customers in the period.
Singer India Ltd reported ₹145 Cr of revenue in the Jun 26 quarter, +56.9% year on year. That is the 4th straight quarter of year-on-year growth. Over 11 years it has compounded at 6.4% a year. The last full year, FY26, came in at ₹557 Cr. The last four reported quarters add to ₹610 Cr.
FY26 revenue came in at ₹557 Cr (+28.9% on the year), capping 11 years at 6.4% compound. The latest quarter (Jun 26) printed ₹145 Cr, +56.9% year on year — the 4th consecutive quarter of year-over-year growth.
Pace check: the last four quarters averaged +44.1% growth against the decade's 6.4% — the current year is running faster than its own long-run rate.
Acceleration check: trailing-twelve-month revenue grew +43.5% over the last 4 quarters against +20.6%/yr over the last 8 — accelerating; TTM profit +305.4% vs +92.3%/yr — accelerating.
Operating margin Operating margin is what is left of every ₹100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.
Singer India Ltd's operating margin is 2.5% in the Jun 26 quarter, +6.5 percentage points against the same quarter a year ago. Across 11 fiscal years the operating margin has ranged 0.4% to 4.5%. The current quarter sits inside that band.
The latest quarter's operating margin is 2.5%, +6.5 pp against the same quarter a year ago. Across 11 fiscal years the operating margin has ranged 0.4%–4.5%.
Why the margin moved: operating margin went +6.5 pp year on year while gross margin went −0.9 pp — the gain came mostly below the gross line: operating leverage, with costs spread over a bigger revenue base.
Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.
Singer India Ltd earned ₹3.0 Cr of net profit in the Jun 26 quarter. Full-year FY26 profit was ₹13.0 Cr. The 11-year compound rate is 7.3%. That is 2.1% of the quarter's revenue. The same quarter a year earlier lost ₹2.4 Cr. 1 of the last 12 reported quarters were loss-making.
Jun 26 profit was ₹3.0 Cr, null year on year. On the full year, FY26 printed ₹13.0 Cr (+85.7%), and the 11-year compound rate is 7.3%.
Pace comparison, last four quarters: profit +168.1% vs revenue +44.1%. Profit is growing faster than sales — fixed costs are being spread over a bigger base, and each extra rupee of revenue drops more to the bottom line.
Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.
Over the last 3 fiscal years 54% of Singer India Ltd's reported profit arrived as operating cash — a gap worth watching. In FY26 that was ₹37.0 Cr of operating cash against ₹13.0 Cr of profit. After ₹22.0 Cr of capital spending, ₹15.0 Cr was left as free cash.
FY26: operating cash of ₹37.0 Cr against reported profit of ₹13.0 Cr, leaving free cash of ₹15.0 Cr after ₹22.0 Cr of capital spending. Across the last 3 fiscal years the conversion rate is 54% of profit.
Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.
🚨 Why conversion sits at 54%: the cash cycle held roughly steady between FY21 and FY26 — so conversion tracks profitability rather than the cycle. Less than 70% of profit arriving as cash is the thing to watch on this page.
Router verdict: the bigger cash user is investment — capital spending ran 3.3× depreciation over three years, so the next section's job is to check what that build-out is buying.
Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).
Singer India Ltd's cash conversion cycle runs 59 days in FY26, up from 49 days in FY21. Capital spending ran ₹30.0 Cr over the last 3 years. At FY26 sales of ₹557 Cr each day of that cycle holds about ₹1.5 Cr, so roughly ₹90.0 Cr sits inside the business at any moment.
FY26: debtors at 25 days, inventory at 96 days — roughly 3.2 months of stock waiting to sell; that is where the cash sits while it waits — for a full cycle of 59 days, looser than FY21's 49.
The full loop: cash goes out to suppliers and production on day 0; stock waits 96 days to sell; customers pay about 25 days after that; and suppliers themselves are paid at 62 days — netting out to the 59-day cycle.
In money terms: at FY26 sales of ₹557 Cr, each day of the cycle holds about ₹1.5 Cr — so the 59-day loop keeps roughly ₹90.0 Cr sitting inside the business at any moment.
On the investment side: capital spending of ₹30.0 Cr over the last 3 fiscal years against ₹9.0 Cr of depreciation — the company is building well ahead of wear-and-tear. Capital work-in-progress stands at ₹1.0 Cr (FY26) — capacity paid for but not yet earning.
The synthesis: the cash is going into capacity, not disappearing into the cycle — the question becomes whether the new capacity earns.
Return on capital Return on capital employed (ROCE) is the profit the whole business earns on all the money in it — equity and debt together. It is the single best test of whether growth creates value or just size.
Singer India Ltd earns a ROCE of 11% in FY26. That is up from a trough of 4% in FY23. A return-on-invested-capital spread against the cost of capital is not computable from what is held here. The wiring behind it is 2.3% net margin on 1.91× asset turns.
FY26 ROCE is 11%, recovered from a FY23 trough of 4% — the full ladder below shows the fall and the climb, undoctored.
Why the return is what it is — the wiring (FY26): 2.3% net margin × 1.91× asset turns × 1.64× balance-sheet leverage ≈ 7.2% on equity. Margin does its share; leverage is a meaningful part of the equation.
Debt Debt-to-equity says how much of the business is funded by borrowings; interest cover says how many times operating profit pays the interest bill. Low and high, respectively, is the safe corner.
Singer India Ltd carries ₹5.0 Cr of borrowings against ₹178 Cr of equity in FY26, a debt-to-equity of 0.03. Operating profit covers the interest bill 15×. Over 5 years borrowings went from ₹2.0 Cr to ₹5.0 Cr. Capital spending ran ₹30.0 Cr across the last 3 of those years.
FY26: borrowings of ₹5.0 Cr against equity of ₹178 Cr — a debt-to-equity of 0.03. Operating profit covers the interest bill 15×. Over 5 years borrowings went from ₹2.0 Cr to ₹5.0 Cr while capital spending ran ₹30.0 Cr in just the last 3 — part of the build-out is riding on borrowed money.
Ownership Who owns the stock, quarter by quarter: promoters (the controlling owners), foreign and domestic institutions, and the public. Steady accumulation by people close to the numbers is a signal; a quiet register is also an answer.
Domestic institutions cut 2.6 points of Singer India Ltd over 8 quarters, the biggest move on the register. That takes domestic institutions to 0.0% of the company. Promoters moved −0.5 points over the same window, to 30.5%. The register is read on the four disclosed classes only; nothing is inferred between filings.
The register over the last two years — Domestic institutions: −2.6 points over 8 quarters to 0.0%; Promoters: −0.5 points over 8 quarters to 30.5%.
🚨 Why the register moved: domestic institutions drove it (−2.6 points), alongside promoters (−0.5 points) — distribution into the market’s bid.
Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.
Singer India Ltd: the Z-score is not available for this stock, so we say so rather than invent one. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure. The debt, cash-flow and return sections above carry the balance-sheet evidence this page does hold, and each of them states its own reporting date.
The safety line in one sentence: the Z-score is not available for this stock, so we say so rather than invent one.
| Company | Score | Price stage | Growth & earnings/35 | Capital efficiency/25 | Valuation/20 | Relative strength/20 |
|---|---|---|---|---|---|---|
| 1Magnus Steel & Infra Ltd517320 | 67.1/100Thin evidence · provisional56% evidence | 27.5/35 Revenue 100% · PAT 100% · OPM change 1.6 pp 83% evidence | 18.5/25 ROCE 171% · OPM 21.3% 76% evidence | 9.2/20 P/E 92.5× · PEG — 15% evidence | 11.9/20 RS sector — · RS bench 46.1% · 1Y 1004.7%11 of 12 weeks ahead to 2026-06-28 25% evidence | |
| Exact sum: 27.5 + 18.5 + 9.2 + 11.9 = 67.1 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 2Vision Infra Equipment Solutions LtdVIESL | 66.8/100Thin evidence · provisional56% evidence | BREAKING OUT | 18.9/35 Revenue — · PAT — · OPM change 0 pp 26% evidence | 19.9/25 ROCE 22.6% · OPM 26% 95% evidence | 10.9/20 P/E 13.8× · PEG — 15% evidence | 17.1/20 RS sector 12.8% · RS bench 34.7% · 1Y 65.9%9 of 12 weeks ahead 100% evidence |
| Exact sum: 18.9 + 19.9 + 10.9 + 17.1 = 66.8 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 3Nupur Recyclers LtdNRL | 66.6/100Favorable setup87% evidence | LEADER | 22.1/35 Revenue 40.6% · PAT 29.8% · OPM change 3.6 pp 95% evidence | 16.6/25 ROCE 15.1% · OPM 11.6% 95% evidence | 8.0/20 P/E 63× · PEG — 50% evidence | 19.9/20 RS sector 84.5% · RS bench 117.1% · 1Y 116.3%12 of 12 weeks ahead 100% evidence |
| Exact sum: 22.1 + 16.6 + 8 + 19.9 = 66.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 4Rashi Peripherals LtdRPTECH | 65.5/100Favorable setup75% evidence | LEADER | 24.3/35 Revenue 40.4% · PAT 50.2% · OPM change -0.3 pp 95% evidence | 14.7/25 ROCE 17% · OPM 3% 76% evidence | 10.6/20 P/E 19.8× · PEG — 15% evidence | 15.9/20 RS sector 64.7% · RS bench 92.3% · 1Y 202.2%12 of 12 weeks ahead 100% evidence |
| Exact sum: 24.3 + 14.7 + 10.6 + 15.9 = 65.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 5Shankara Buildpro LtdBUILDPRO | 62.7/100Mixed-positive evidence63% evidence | BREAKING OUT | 25.1/35 Revenue 26.3% · PAT 41.9% · OPM change -0.2 pp 100% evidence | 17.4/25 ROCE 39% · OPM 3.2% 100% evidence | 10.2/20 P/E 22.8× · PEG — 15% evidence | 10.0/20 RS sector — · RS bench — · 1Y —10 of 12 weeks ahead 0% evidence |
| Exact sum: 25.1 + 17.4 + 10.2 + 10 = 62.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 6Mangalam Global Enterprise LtdMGEL | 61.7/100Mixed-positive evidence80% evidence | BASING | 25.1/35 Revenue 41.4% · PAT 100% · OPM change 0.5 pp 95% evidence | 15.9/25 ROCE 17% · OPM 1.9% 95% evidence | 11.0/20 P/E 13.7× · PEG — 15% evidence | 9.7/20 RS sector -4.3% · RS bench 15.3% · 1Y -11%5 of 12 weeks ahead 100% evidence |
| Exact sum: 25.1 + 15.9 + 11 + 9.7 = 61.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 7Pramara Promotions LtdPRAMARA | 61.6/100Mixed-positive evidence69% evidence | 22.3/35 Revenue 72.7% · PAT 100% · OPM change 1 pp 59% evidence | 14.3/25 ROCE 15% · OPM 14.6% 95% evidence | 14.3/20 P/E 14.2× · PEG — 50% evidence | 10.7/20 RS sector 7.9% · RS bench -60.1% · 1Y -63.3%10 of 12 weeks ahead 70% evidence | |
| Exact sum: 22.3 + 14.3 + 14.3 + 10.7 = 61.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 8Tembo Global Industries LtdTEMBO | 60.7/100Mixed-positive evidence80% evidence | TURNING | 21.7/35 Revenue 34% · PAT 55.7% · OPM change 5 pp 95% evidence | 18.5/25 ROCE 22.8% · OPM 16% 95% evidence | 11.3/20 P/E 10.4× · PEG — 15% evidence | 9.2/20 RS sector -16.2% · RS bench 1.9% · 1Y 1.3%2 of 12 weeks ahead 100% evidence |
| Exact sum: 21.7 + 18.5 + 11.3 + 9.2 = 60.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 9Arisinfra Solutions LtdARIS | 58.4/100Mixed-positive evidence65% evidence | BREAKING OUT | 21.7/35 Revenue 45.3% · PAT 100% · OPM change 2 pp 95% evidence | 15.0/25 ROCE 15.6% · OPM 11% 95% evidence | 10.6/20 P/E 17.2× · PEG — 15% evidence | 11.1/20 RS sector — · RS bench 15.2% · 1Y -12.1%7 of 12 weeks ahead 25% evidence |
| Exact sum: 21.7 + 15 + 10.6 + 11.1 = 58.4 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 10Ivalue Infosolutions LtdIVALUE | 58.4/100Mixed-positive evidence65% evidence | ASLEEP | 20.2/35 Revenue 5.4% · PAT 22.1% · OPM change 5.6 pp 95% evidence | 18.6/25 ROCE 25.4% · OPM 10% 95% evidence | 11.2/20 P/E 11.2× · PEG — 15% evidence | 8.4/20 RS sector — · RS bench -10.3% · 1Y -20.9%5 of 12 weeks ahead 25% evidence |
| Exact sum: 20.2 + 18.6 + 11.2 + 8.4 = 58.4 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 11Euro Pratik Sales LtdEUROPRATIK | 57.7/100Mixed-positive evidence78% evidence | ASLEEP | 14.9/35 Revenue 23.9% · PAT 29% · OPM change -8 pp 100% evidence | 19.4/25 ROCE 36.9% · OPM 26% 100% evidence | 15.4/20 P/E 22.6× · PEG 0.62 65% evidence | 8.0/20 RS sector — · RS bench -26.3% · 1Y -18.9%5 of 12 weeks ahead 25% evidence |
| Exact sum: 14.9 + 19.4 + 15.4 + 8 = 57.7 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity. | ||||||
| 12Singer India Ltdthis pageSINGERIND | 57.3/100Thin evidence · provisional52% evidence | 26.1/35 Revenue 43.5% · PAT 100% · OPM change 6.5 pp 71% evidence | 10.2/25 ROCE 10.9% · OPM 2.5% 76% evidence | 10.1/20 P/E 25.9× · PEG — 15% evidence | 10.9/20 RS sector — · RS bench 9.7% · 1Y — 25% evidence | |
| Exact sum: 26.1 + 10.2 + 10.1 + 10.9 = 57.3 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 13Aayush Art and Bullion Ltd540718 | 56.2/100Thin evidence · provisional54% evidence | BREAKING OUT | 21.0/35 Revenue 100% · PAT — · OPM change 1.6 pp 35% evidence | 13.1/25 ROCE 18.9% · OPM 6% 76% evidence | 8.8/20 P/E 247× · PEG — 15% evidence | 13.3/20 RS sector -2.3% · RS bench 17.8% · 1Y 28.5%6 of 12 weeks ahead 100% evidence |
| Exact sum: 21 + 13.1 + 8.8 + 13.3 = 56.2 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 14Sudarshan Pharma Industries Ltd543828 | 55.2/100Mixed-positive evidence82% evidence | FADING | 20.5/35 Revenue 32.9% · PAT 24.3% · OPM change 1.5 pp 95% evidence | 13.7/25 ROCE 15.1% · OPM 9.1% 76% evidence | 8.4/20 P/E 37× · PEG — 50% evidence | 12.6/20 RS sector 8.1% · RS bench 28.7% · 1Y 40.7%10 of 12 weeks ahead 100% evidence |
| Exact sum: 20.5 + 13.7 + 8.4 + 12.6 = 55.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 15Lloyds Enterprises LtdLLOYDSENT | 55.0/100Mixed-positive evidence75% evidence | TURNING | 17.9/35 Revenue 33% · PAT -21.4% · OPM change 9 pp 95% evidence | 11.2/25 ROCE 3.7% · OPM 16% 76% evidence | 9.1/20 P/E 104× · PEG — 15% evidence | 16.8/20 RS sector 4.9% · RS bench 25.8% · 1Y 23.5%9 of 12 weeks ahead 100% evidence |
| Exact sum: 17.9 + 11.2 + 9.1 + 16.8 = 55 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 16Onix Solar Energy LtdONIXSOLAR | 54.7/100Mixed-positive evidence69% evidence | ASLEEP | 20.6/35 Revenue 26.2% · PAT 100% · OPM change 23 pp 95% evidence | 11.7/25 ROCE 11.3% · OPM 30% 76% evidence | 10.0/20 P/E 27.7× · PEG — 15% evidence | 12.4/20 RS sector 68.4% · RS bench -22.9% · 1Y 24.9%0 of 1 week ahead 70% evidence |
| Exact sum: 20.6 + 11.7 + 10 + 12.4 = 54.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 17Patel Retail LtdPATELRMART | 53.8/100Mixed-positive evidence65% evidence | ASLEEP | 17.9/35 Revenue 42.3% · PAT 59.7% · OPM change -2.2 pp 95% evidence | 14.4/25 ROCE 15.6% · OPM 6.1% 95% evidence | 10.7/20 P/E 16.9× · PEG — 15% evidence | 10.8/20 RS sector — · RS bench 8% · 1Y -5.2%4 of 12 weeks ahead 25% evidence |
| Exact sum: 17.9 + 14.4 + 10.7 + 10.8 = 53.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 18Bizotic Commercial Ltd543926 | 52.9/100Thin evidence · provisional58% evidence | TURNING | 19.7/35 Revenue — · PAT — · OPM change 0 pp 26% evidence | 18.7/25 ROCE 26.8% · OPM 8% 76% evidence | 9.0/20 P/E 40.2× · PEG — 50% evidence | 5.5/20 RS sector -84% · RS bench -0.7% · 1Y -77.1%1 of 12 weeks ahead 100% evidence |
| Exact sum: 19.7 + 18.7 + 9 + 5.5 = 52.9 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 19Prostarm Info Systems LtdPROSTARM | 51.7/100Mixed-positive evidence65% evidence | TURNING | 16.6/35 Revenue 30.5% · PAT 19.1% · OPM change 1.4 pp 95% evidence | 16.0/25 ROCE 18% · OPM 8.5% 95% evidence | 10.4/20 P/E 22.3× · PEG — 15% evidence | 8.7/20 RS sector — · RS bench -4.7% · 1Y -31.7%2 of 12 weeks ahead 25% evidence |
| Exact sum: 16.6 + 16 + 10.4 + 8.7 = 51.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 20Pervasive Commodities Ltd517172 | 51.0/100Thin evidence · provisional52% evidence | TURNING | 16.6/35 Revenue 25.6% · PAT -8.3% · OPM change -6.1 pp 95% evidence | 14.4/25 ROCE 22.1% · OPM -10.2% 76% evidence | 10.0/20 P/E — · PEG — 0% evidence | 10.0/20 RS sector — · RS bench — · 1Y —3 of 3 weeks ahead 0% evidence |
| Exact sum: 16.6 + 14.4 + 10 + 10 = 51 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 21BMW Ventures LtdBMW | 49.8/100Thin evidence · provisional55% evidence | 16.7/35 Revenue 18.5% · PAT 24.2% · OPM change -0.6 pp 95% evidence | 12.0/25 ROCE 12% · OPM 3.4% 76% evidence | 11.1/20 P/E 12.2× · PEG — 15% evidence | 10.0/20 RS sector — · RS bench — · 1Y -18.7%0 of 10 weeks ahead to 2026-08-23 0% evidence | |
| Exact sum: 16.7 + 12 + 11.1 + 10 = 49.8 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 22Fabtech Technologies LtdFABTECH | 49.4/100Thin evidence · provisional57% evidence | ASLEEP | 17.5/35 Revenue 14.2% · PAT 41% · OPM change 14.8 pp 71% evidence | 12.4/25 ROCE 13.6% · OPM 5.7% 95% evidence | 11.1/20 P/E 13× · PEG — 15% evidence | 8.4/20 RS sector — · RS bench -12.2% · 1Y -27.1%0 of 12 weeks ahead 25% evidence |
| Exact sum: 17.5 + 12.4 + 11.1 + 8.4 = 49.4 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 23Yogi LtdYOGI | 48.6/100Thin evidence · provisional58% evidence | TURNING | 20.1/35 Revenue 97.5% · PAT 68.1% · OPM change -5.9 pp 62% evidence | 10.0/25 ROCE 12.6% · OPM 2.6% 76% evidence | 9.4/20 P/E 54.9× · PEG — 15% evidence | 9.1/20 RS sector -6.5% · RS bench 2.2% · 1Y -6.7%0 of 1 week ahead 70% evidence |
| Exact sum: 20.1 + 10 + 9.4 + 9.1 = 48.6 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 24SG Mart LtdSGMART | 48.2/100Mixed-negative evidence93% evidence | LEADER | 13.6/35 Revenue 10.4% · PAT 14.7% · OPM change 1.4 pp 100% evidence | 8.4/25 ROCE 10.2% · OPM 4.5% 100% evidence | 8.2/20 P/E 75.3× · PEG 1.92 65% evidence | 18.0/20 RS sector 27.3% · RS bench 50.1% · 1Y 104.4%12 of 12 weeks ahead 100% evidence |
| Exact sum: 13.6 + 8.4 + 8.2 + 18 = 48.2 · Decision use: Price leads the evidence: RS versus the benchmark is 50.1%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 25Shiv Aum Steels LtdSHIVAUM | 46.9/100Thin evidence · provisional55% evidence | BREAKING OUT | 16.8/35 Revenue — · PAT — · OPM change 1.3 pp 45% evidence | 11.4/25 ROCE 8% · OPM 4.7% 95% evidence | 6.6/20 P/E 79.6× · PEG — 50% evidence | 12.1/20 RS sector — · RS bench 65.9% · 1Y —9 of 9 weeks ahead 25% evidence |
| Exact sum: 16.8 + 11.4 + 6.6 + 12.1 = 46.9 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 26Dhunseri Ventures LtdDVL | 46.7/100Mixed-negative evidence87% evidence | BREAKING OUT | 12.5/35 Revenue -20% · PAT 31.7% · OPM change -12 pp 95% evidence | 9.4/25 ROCE 6.7% · OPM 39% 95% evidence | 12.4/20 P/E 5.1× · PEG — 50% evidence | 12.4/20 RS sector -8.2% · RS bench 11.7% · 1Y -23.1%8 of 12 weeks ahead 100% evidence |
| Exact sum: 12.5 + 9.4 + 12.4 + 12.4 = 46.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 27State Trading Corporation of India LtdSTCINDIA | 46.7/100Thin evidence · provisional57% evidence | ASLEEP | 22.8/35 Revenue — · PAT 100% · OPM change — 57% evidence | 7.6/25 ROCE 7.6% · OPM — 80% evidence | 10.8/20 P/E 15.3× · PEG — 15% evidence | 5.5/20 RS sector -28.7% · RS bench -6.2% · 1Y -21.2%0 of 12 weeks ahead 70% evidence |
| Exact sum: 22.8 + 7.6 + 10.8 + 5.5 = 46.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 28Hexa Tradex LtdHEXATRADEX | 42.4/100Mixed-negative evidence65% evidence | TURNING | 17.0/35 Revenue 0.4% · PAT 70.3% · OPM change 13.6 pp 71% evidence | 6.2/25 ROCE -0.1% · OPM — 80% evidence | 10.0/20 P/E — · PEG — 0% evidence | 9.2/20 RS sector -17.1% · RS bench 0.7% · 1Y -10%0 of 12 weeks ahead 100% evidence |
| Exact sum: 17 + 6.2 + 10 + 9.2 = 42.4 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 29MMTC LtdMMTC | 42.0/100Mixed-negative evidence96% evidence | ASLEEP | 15.0/35 Revenue 0% · PAT 100% · OPM change -1270 pp 100% evidence | 7.8/25 ROCE 8.7% · OPM — 84% evidence | 15.8/20 P/E 41.9× · PEG 0.92 100% evidence | 3.4/20 RS sector -22.4% · RS bench -6% · 1Y -14.1%0 of 12 weeks ahead 100% evidence |
| Exact sum: 15 + 7.8 + 15.8 + 3.4 = 42 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity. | ||||||
| 30Cropster Agro Ltd523105 | 41.1/100Mixed-negative evidence69% evidence | BASING | 15.3/35 Revenue 28.4% · PAT 6.5% · OPM change 1.7 pp 95% evidence | 11.7/25 ROCE 12.4% · OPM 9.8% 76% evidence | 10.8/20 P/E 14.2× · PEG — 15% evidence | 3.3/20 RS sector -72.7% · RS bench -74.2% · 1Y -87.9%0 of 5 weeks ahead 70% evidence |
| Exact sum: 15.3 + 11.7 + 10.8 + 3.3 = 41.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 31RRP Semiconductor LtdRRP | 40.8/100Thin evidence · provisional54% evidence | 11.2/35 Revenue -80% · PAT -80% · OPM change 3.3 pp 71% evidence | 5.6/25 ROCE -32.7% · OPM — 61% evidence | 10.0/20 P/E — · PEG — 0% evidence | 14.0/20 RS sector 65.3% · RS bench 0.8% · 1Y 23.7%0 of 1 week ahead to 2026-08-23 70% evidence | |
| Exact sum: 11.2 + 5.6 + 10 + 14 = 40.8 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 32Le Merite Exports LtdLEMERITE | 40.0/100Thin evidence · provisional57% evidence | 18.0/35 Revenue — · PAT — · OPM change -15.5 pp 45% evidence | 6.8/25 ROCE 9.9% · OPM -10.7% 95% evidence | 9.1/20 P/E 94.5× · PEG — 15% evidence | 6.1/20 RS sector -9% · RS bench -68.5% · 1Y -95%0 of 2 weeks ahead 70% evidence | |
| Exact sum: 18 + 6.8 + 9.1 + 6.1 = 40 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 33Hardwyn India LtdHARDWYN | 39.9/100Mixed-negative evidence87% evidence | ASLEEP | 13.5/35 Revenue 2.6% · PAT -8.5% · OPM change -0.2 pp 95% evidence | 12.3/25 ROCE 4.8% · OPM 13% 95% evidence | 12.5/20 P/E 50.8× · PEG — 50% evidence | 1.6/20 RS sector -38.6% · RS bench -25.9% · 1Y 2.1%0 of 12 weeks ahead 100% evidence |
| Exact sum: 13.5 + 12.3 + 12.5 + 1.6 = 39.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 34Blue Pearl Agriventures LtdBPAGRI | 39.2/100Mixed-negative evidence69% evidence | 20.0/35 Revenue 19.3% · PAT 59.1% · OPM change 0.3 pp 95% evidence | 6.2/25 ROCE 2.2% · OPM 3.3% 76% evidence | 8.7/20 P/E 514× · PEG — 15% evidence | 4.3/20 RS sector -33.5% · RS bench -82.5% · 1Y -90.8%1 of 12 weeks ahead to 2026-08-23 70% evidence | |
| Exact sum: 20 + 6.2 + 8.7 + 4.3 = 39.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 35Adani Enterprises LtdADANIENT | 39.0/100Mixed-negative evidence93% evidence | ASLEEP | 14.1/35 Revenue 18.1% · PAT 4.2% · OPM change 0 pp 100% evidence | 8.3/25 ROCE 5.8% · OPM 15% 100% evidence | 7.6/20 P/E 161× · PEG 1.96 65% evidence | 9.0/20 RS sector -1.4% · RS bench 17.9% · 1Y 14.2%7 of 12 weeks ahead 100% evidence |
| Exact sum: 14.1 + 8.3 + 7.6 + 9 = 39 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 36Neueon Corporation LtdNEUEON | 37.8/100Thin evidence · provisional59% evidence | TURNING | 9.1/35 Revenue 17.8% · PAT -80% · OPM change -1039 pp 71% evidence | 3.9/25 ROCE -40.4% · OPM — 80% evidence | 10.0/20 P/E — · PEG — 0% evidence | 14.8/20 RS sector 12.7% · RS bench 25.1% · 1Y —0 of 12 weeks ahead 70% evidence |
| Exact sum: 9.1 + 3.9 + 10 + 14.8 = 37.8 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 37PTC India LtdPTC | 37.7/100Mixed-negative evidence82% evidence | ASLEEP | 11.2/35 Revenue 13.3% · PAT -43.1% · OPM change -3.9 pp 95% evidence | 12.7/25 ROCE 13.4% · OPM 3.1% 76% evidence | 9.2/20 P/E 9× · PEG — 50% evidence | 4.6/20 RS sector -20.7% · RS bench -4.1% · 1Y -7.4%0 of 12 weeks ahead 100% evidence |
| Exact sum: 11.2 + 12.7 + 9.2 + 4.6 = 37.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 38Riddhi Siddhi Gluco Biols Ltd524480 | 36.9/100Mixed-negative evidence82% evidence | TURNING | 12.3/35 Revenue -38% · PAT 38.4% · OPM change -2.8 pp 95% evidence | 6.5/25 ROCE 2.7% · OPM -3% 76% evidence | 6.4/20 P/E 35.8× · PEG — 50% evidence | 11.7/20 RS sector 4% · RS bench 23.7% · 1Y 26.7%7 of 12 weeks ahead 100% evidence |
| Exact sum: 12.3 + 6.5 + 6.4 + 11.7 = 36.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 39Kothari Industrial Corporation LtdKOTIC | 34.7/100Adverse evidence63% evidence | TURNING | 18.7/35 Revenue 75.9% · PAT -80% · OPM change -41.8 pp 71% evidence | 2.0/25 ROCE -11.4% · OPM -43% 95% evidence | 10.0/20 P/E — · PEG — 0% evidence | 4.0/20 RS sector -58.6% · RS bench -29.1% · 1Y -71.9%0 of 12 weeks ahead 70% evidence |
| Exact sum: 18.7 + 2 + 10 + 4 = 34.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 40BN Agrochem LtdBNAGROCHEM | 32.3/100Adverse evidence77% evidence | BASING | 12.8/35 Revenue 84.5% · PAT -61% · OPM change -9.4 pp 100% evidence | 4.2/25 ROCE 4.4% · OPM 2.3% 100% evidence | 9.0/20 P/E 130× · PEG — 15% evidence | 6.3/20 RS sector -16.7% · RS bench -17.4% · 1Y -38.5%3 of 12 weeks ahead 70% evidence |
| Exact sum: 12.8 + 4.2 + 9 + 6.3 = 32.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 41Shanti Overseas (India) LtdSHANTI | 31.5/100Thin evidence · provisional56% evidence | 11.3/35 Revenue -63.4% · PAT 100% · OPM change -200.5 pp 40% evidence | 4.5/25 ROCE -25.2% · OPM -216.5% 71% evidence | 12.1/20 P/E 3× · PEG — 50% evidence | 3.6/20 RS sector -60.4% · RS bench -49.7% · 1Y -46.8%0 of 12 weeks ahead to 2026-03-29 70% evidence | |
| Exact sum: 11.3 + 4.5 + 12.1 + 3.6 = 31.5 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 42Uniphos Enterprises LtdUNIENTER | 31.3/100Adverse evidence69% evidence | ASLEEP | 12.3/35 Revenue -77.1% · PAT 100% · OPM change -0.9 pp 71% evidence | 4.5/25 ROCE 0.8% · OPM — 80% evidence | 9.9/20 P/E 29.9× · PEG — 50% evidence | 4.6/20 RS sector -43.6% · RS bench -19.9% · 1Y -41.2%0 of 12 weeks ahead 70% evidence |
| Exact sum: 12.3 + 4.5 + 9.9 + 4.6 = 31.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 43Oswal Agro Mills LtdOSWALAGRO | 24.7/100Adverse evidence67% evidence | 2.9/35 Revenue -80% · PAT -80% · OPM change -21782.3 pp 95% evidence | 7.7/25 ROCE 2% · OPM — 80% evidence | 10.0/20 P/E — · PEG — 0% evidence | 4.1/20 RS sector -50.3% · RS bench -30.3% · 1Y -52.7%0 of 11 weeks ahead 70% evidence | |
| Exact sum: 2.9 + 7.7 + 10 + 4.1 = 24.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 44Susan Electricals India Ltd544793 | 58.9/100Thin evidence · provisional31% evidence | TURNING | 20.6/35 Revenue — · PAT — · OPM change 7.8 pp 26% evidence | 18.1/25 ROCE 37% · OPM 11.9% 76% evidence | 10.2/20 P/E 25.2× · PEG — 15% evidence | 10.0/20 RS sector — · RS bench — · 1Y —1 of 1 week ahead 0% evidence |
| Exact sum: 20.6 + 18.1 + 10.2 + 10 = 58.9 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 45Q-Line Biotech LtdQLINE | 58.0/100Thin evidence · provisional31% evidence | TURNING | 18.1/35 Revenue — · PAT — · OPM change 10 pp 13% evidence | 19.8/25 ROCE 22.4% · OPM 31% 95% evidence | 10.1/20 P/E 27.2× · PEG — 15% evidence | 10.0/20 RS sector — · RS bench — · 1Y —4 of 4 weeks ahead 0% evidence |
| Exact sum: 18.1 + 19.8 + 10.1 + 10 = 58 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 46DC Infotech & Communication LtdDCI | 57.4/100Thin evidence · provisional35% evidence | 18.4/35 Revenue — · PAT — · OPM change 0.3 pp 24% evidence | 17.7/25 ROCE 22.9% · OPM 4.7% 76% evidence | 10.3/20 P/E 22.7× · PEG — 15% evidence | 11.0/20 RS sector — · RS bench 10.5% · 1Y —1 of 1 week ahead 25% evidence | |
| Exact sum: 18.4 + 17.7 + 10.3 + 11 = 57.4 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 47Mardia Samyoung Capillary Tubes Company LtdMSCTC | 57.0/100Thin evidence · provisional32% evidence | 20.9/35 Revenue 100% · PAT 100% · OPM change — 29% evidence | 15.3/25 ROCE 22.6% · OPM 15.3% 57% evidence | 8.6/20 P/E 687× · PEG — 15% evidence | 12.2/20 RS sector — · RS bench 74.6% · 1Y 44.1%6 of 12 weeks ahead to 2026-03-08 25% evidence | |
| Exact sum: 20.9 + 15.3 + 8.6 + 12.2 = 57 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 48SK Minerals & Additives Ltd544584 | 55.5/100Thin evidence · provisional36% evidence | BREAKING OUT | 16.5/35 Revenue — · PAT — · OPM change 1.3 pp 39% evidence | 19.1/25 ROCE 26.2% · OPM 10.7% 76% evidence | 9.9/20 P/E 28.4× · PEG — 15% evidence | 10.0/20 RS sector — · RS bench — · 1Y —6 of 7 weeks ahead 0% evidence |
| Exact sum: 16.5 + 19.1 + 9.9 + 10 = 55.5 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 49Proventus Agrocom LtdPROV | 55.3/100Thin evidence · provisional48% evidence | BREAKING OUT | 19.5/35 Revenue — · PAT — · OPM change 0.2 pp 26% evidence | 12.7/25 ROCE 11.5% · OPM 1.8% 95% evidence | 11.3/20 P/E 48.3× · PEG — 50% evidence | 11.8/20 RS sector — · RS bench 44.2% · 1Y —12 of 12 weeks ahead 25% evidence |
| Exact sum: 19.5 + 12.7 + 11.3 + 11.8 = 55.3 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 50Arvaya Healthcare LtdARVAYA | 54.7/100Thin evidence · provisional19% evidence | 18.6/35 Revenue — · PAT — · OPM change 46.1 pp 10% evidence | 12.3/25 ROCE — · OPM 13% 30% evidence | 11.4/20 P/E 3.9× · PEG — 15% evidence | 12.4/20 RS sector — · RS bench 104.2% · 1Y — 25% evidence | |
| Exact sum: 18.6 + 12.3 + 11.4 + 12.4 = 54.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 51Monika Alcobev LtdMONIKA | 53.9/100Thin evidence · provisional22% evidence | 16.4/35 Revenue — · PAT — · OPM change -2 pp 15% evidence | 17.0/25 ROCE 21% · OPM 15% 57% evidence | 10.5/20 P/E 20.4× · PEG — 15% evidence | 10.0/20 RS sector — · RS bench — · 1Y -12%0 of 12 weeks ahead to 2026-03-08 0% evidence | |
| Exact sum: 16.4 + 17 + 10.5 + 10 = 53.9 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 52Shah Foods Ltd519031 | 53.5/100Thin evidence · provisional18% evidence | BREAKING OUT | 17.1/35 Revenue — · PAT — · OPM change -10.7 pp 7% evidence | 15.3/25 ROCE — · OPM 18% 30% evidence | 8.9/20 P/E 233× · PEG — 15% evidence | 12.2/20 RS sector — · RS bench 69.1% · 1Y —7 of 7 weeks ahead 25% evidence |
| Exact sum: 17.1 + 15.3 + 8.9 + 12.2 = 53.5 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 53Manbro Industries Ltd512595 | 51.0/100Thin evidence · provisional22% evidence | 18.3/35 Revenue — · PAT — · OPM change 32.8 pp 5% evidence | 13.2/25 ROCE — · OPM 6.6% 23% evidence | 10.0/20 P/E — · PEG — 0% evidence | 9.5/20 RS sector -17.3% · RS bench 37.2% · 1Y 83.1%12 of 12 weeks ahead to 2026-05-03 70% evidence | |
| Exact sum: 18.3 + 13.2 + 10 + 9.5 = 51 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 54Satani Bearings Ltd505703 | 45.4/100Thin evidence · provisional38% evidence | BREAKING OUT | 20.5/35 Revenue — · PAT 100% · OPM change — 33% evidence | 4.7/25 ROCE 1% · OPM -3.7% 76% evidence | 8.6/20 P/E 5323× · PEG — 15% evidence | 11.6/20 RS sector — · RS bench 27.6% · 1Y 169.8%4 of 11 weeks ahead 25% evidence |
| Exact sum: 20.5 + 4.7 + 8.6 + 11.6 = 45.4 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 55Keto Motors Ltd537392 | 43.2/100Thin evidence · provisional38% evidence | BREAKING OUT | 16.2/35 Revenue — · PAT 100% · OPM change — 33% evidence | 6.0/25 ROCE -0.3% · OPM 10.7% 76% evidence | 8.5/20 P/E 6745× · PEG — 15% evidence | 12.5/20 RS sector — · RS bench 191.6% · 1Y —7 of 7 weeks ahead 25% evidence |
| Exact sum: 16.2 + 6 + 8.5 + 12.5 = 43.2 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 56A-1 LtdA1L | 40.9/100Thin evidence · provisional50% evidence | 16.1/35 Revenue 8.3% · PAT -30.6% · OPM change -0.9 pp 53% evidence | 10.7/25 ROCE 10.6% · OPM 2.9% 57% evidence | 8.7/20 P/E 383× · PEG — 15% evidence | 5.4/20 RS sector -24.5% · RS bench -16% · 1Y -11.7%6 of 12 weeks ahead to 2026-03-08 70% evidence | |
| Exact sum: 16.1 + 10.7 + 8.7 + 5.4 = 40.9 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 57Aerpace Industries Ltd534733 | 40.5/100Thin evidence · provisional32% evidence | TURNING | 13.0/35 Revenue — · PAT -80% · OPM change — 33% evidence | 5.5/25 ROCE -21.5% · OPM — 61% evidence | 10.0/20 P/E — · PEG — 0% evidence | 12.0/20 RS sector — · RS bench 50.7% · 1Y —1 of 1 week ahead 25% evidence |
| Exact sum: 13 + 5.5 + 10 + 12 = 40.5 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 58Prabhatam Infra Venture LtdPRABHATAM | 39.2/100Thin evidence · provisional22% evidence | 16.1/35 Revenue — · PAT -80% · OPM change — 8% evidence | 3.1/25 ROCE -97.1% · OPM -23.1% 76% evidence | 10.0/20 P/E — · PEG — 0% evidence | 10.0/20 RS sector — · RS bench — · 1Y — 0% evidence | |
| Exact sum: 16.1 + 3.1 + 10 + 10 = 39.2 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
Missing observations are not scored as bad. Their missing weight lowers confidence and pulls the final score toward neutral. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step curve the sector itself is placed on — basing, turning, breaking out, leader, fading, asleep — read from how many weeks running it has led NIFTY 500 and whether that lead is widening or shrinking. It describes where the PRICE stands, not the earnings trajectory and not a recommendation, and it is left blank for a company whose weekly history is too short or too stale to read.
Frequently asked questions
What is Singer India Ltd's share price today?
Singer India Ltd trades at ₹77.7. The company is valued at ₹483 Cr. The stock sits at 69% of its 52-week range of ₹65–₹83, +6.8% versus its 200-day average. On the tape, the price is in a confirmed uptrend, 4 weeks in. — as of 1 October 2026.
What were Singer India Ltd's latest quarterly results?
Singer India Ltd reported revenue of ₹145 Cr and net profit of ₹3.0 Cr for the Jun 26 quarter. Earnings per share were ₹0.48. The operating margin was 2.5%, 6.5 pp higher than a year earlier. — as of 1 October 2026.
What is Singer India Ltd's revenue?
Singer India Ltd reported revenue of ₹145 Cr in the Jun 26 quarter, +56.9% year on year. For the full FY26 fiscal year, revenue was ₹557 Cr (+28.9%). Over the last 11 years revenue compounded at 6.4% a year. — as of 1 October 2026.
What is Singer India Ltd's profit?
Singer India Ltd earned ₹3.0 Cr of net profit in the Jun 26 quarter. Full-year FY26 profit was ₹13.0 Cr. The operating margin ran 2.5% in the latest quarter. — as of 1 October 2026.
What is Singer India Ltd's market cap?
Singer India Ltd's market capitalisation is ₹483 Cr at a share price of ₹77.7. Market cap is the share price multiplied by shares outstanding, so it is restated whenever the price moves. — as of 1 October 2026.
What is Singer India Ltd's P/E ratio?
Singer India Ltd trades at a P/E of 25.9×, at the 22nd percentile of its own 10-year range, against a long-run median of 33.8×. This is a comparison with the stock's own history, not a value call — as of 1 October 2026.
Does Singer India Ltd pay a dividend?
Yes — Singer India Ltd's dividend payout was 20% of profit in FY26, and it recorded a payout in 7 of its last 11 reported fiscal years. This page holds the payout ratio, not a per-share amount. — as of 1 October 2026.
Is Singer India Ltd overvalued?
On its own history, Singer India Ltd looks cheap: its P/E of 25.9× has been cheaper only 22% of the time in 10 years (long-run median 33.8×). That is a percentile read against the stock's own past, not a price opinion or a direction call. — as of 1 October 2026.
How is Singer India Ltd performing?
Singer India Ltd is in a confirmed uptrend, 4 weeks in. This describes what the data did, not a rating. — as of 1 October 2026.
What stage is Singer India Ltd in?
Mixed — revenue growth is rising at +56.9% (single-quarter readings) while profit growth is decelerating from its peak at +45.7% (single-quarter readings) — the curves disagree, so the per-curve reads carry the story. The read comes from the last 12 quarters of growth (revenue growth +56.9% latest, profit growth +45.7% latest) plus the ROCE curve, classified by deterministic rules — a trajectory read, not a buy or sell call — as of 1 October 2026.
Is Singer India Ltd in an uptrend?
Yes — the price is in a confirmed uptrend (week 4 of stage 2), trading +6.8% versus its 200-day average and at 69% of its 52-week range. Price stages cycle base → advance → top → decline, and the stage names where this stock sits in that cycle — as of 1 October 2026.
Will Singer India Ltd's share price go up?
This page publishes no price forecast for Singer India Ltd. What it measures instead: the share price is ₹77.7, the price is in a confirmed uptrend 4 weeks in. Its P/E of 25.9× sits at the 22nd percentile of its own 10-year range. — as of 1 October 2026.
Who owns Singer India Ltd?
Promoters hold 30.5% of Singer India Ltd, foreign institutions null%, domestic institutions 0.0% and the public 68.7% (latest quarter). The biggest move on the register over the last two years: Domestic institutions cut 2.6 points over 8 quarters. — as of 1 October 2026.
Does Singer India Ltd have too much debt?
No — Singer India Ltd's debt-to-equity is 0.03, and operating profit covers the interest bill 15×. FY26 borrowings were ₹5.0 Cr against equity of ₹178 Cr. The returns on this page are earned, not borrowed — as of 1 October 2026.
What is Singer India Ltd's capex?
Singer India Ltd spent ₹30.0 Cr on capital expenditure over the last 3 fiscal years, a figure derived from the change in fixed assets plus depreciation. In FY26 alone that was ₹22.0 Cr, with ₹1.0 Cr in capital work-in-progress — capacity paid for but not yet earning. — as of 1 October 2026.
What is Singer India Ltd's cash flow?
Singer India Ltd generated ₹37.0 Cr of operating cash flow in FY26 and ₹15.0 Cr of free cash flow after ₹22.0 Cr of capital spending. Reported profit that year was ₹13.0 Cr, so operating cash ran ahead of profit. Cash-flow resolution for India is annual. — as of 1 October 2026.
Is Singer India Ltd's profit real cash?
Not fully — over the last 3 fiscal years, 54% of Singer India Ltd's reported profit arrived as operating cash. In FY26, operating cash was ₹37.0 Cr against reported profit of ₹13.0 Cr. The cash then goes mostly into building capacity. Cash-flow resolution is annual — as of 1 October 2026.
Where is Singer India Ltd in its business cycle?
Singer India Ltd's FY26 operating margin was 2.8%, against a 11-year band of 0.4%–4.5%: mid-band by its own history — neither the peak that precedes mean-reversion nor the trough that precedes recovery. The latest quarter ran 2.5%. Profitability versus a company's own long band is the cleanest cycle clock this page holds — as of 1 October 2026.
What could break the Singer India Ltd story?
The sharpest disagreement: profits are rising, but only 54% of the last 3 years' profit arrived as operating cash — the gap between the P&L and the bank account is the thing to watch. Mechanically, two Friday closes in a row below the 200-day average would end the price trend — that is the exit rule this page tracks — as of 1 October 2026.
Is Singer India Ltd a stock worth studying right now?
This is not investment advice. The machine read: Singer India Ltd is coiled. The quarters are improving, yet the P/E sits at the 22nd percentile of its own 10-year range — the business is moving before the market. The sharpest open question: whether the cash starts following the profit. Every number on this page is drawn deterministically from the raw series, with no forecasts and no price opinions — as of 1 October 2026.
Not SEBI Registered !! Not Investment advice !!